|
293 Companies |
|
490 Products |
|
490 Products |
|
199 Mechanisms of Action |
|
25 Trials |
|
7787 News |
|
| «12...8283848586878889909192...156157» |
- | Afrezza (recombinant human insulin inhalation) / MannKind
Trial completion, Trial primary completion date: A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro (clinicaltrials.gov) - Oct 17, 2014
P2, N=29, Completed, Sponsor: Mannkind Corporation
Not yet recruiting --> Completed | Trial primary completion date: Jul 2008 --> Nov 2008
- Enrollment change, Trial termination, Trial primary completion date: Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 15, 2014
P2, N=7, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Completed | Trial primary completion date: Jul 2008 --> Nov 2008 N=78 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jul 2014; Due to slow enrollment
- | Benlysta (belimumab) / GSK
Enrollment change, IO biomarker: A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy (clinicaltrials.gov) - Oct 15, 2014
P2, N=14, Active, not recruiting, Sponsor: GlaxoSmithKline
N=78 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Jul 2014; Due to slow enrollment N=18 --> 14
- || Gardasil (quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine) / UniQuest
New P3 trial: Immunogenicity of HPV Vaccine in Immunosuppressed Children (clinicaltrials.gov) - Oct 15, 2014
P3, N=55, Active, not recruiting, Sponsor: The University of New South Wales
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, Enrollment change, Trial primary completion date: PASSION: Observational Study to Explore the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP) (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=1000, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=18 --> 14 Recruiting --> Active, not recruiting | N=1500 --> 1000 | Trial primary completion date: Nov 2016 --> Mar 2016
- |||| GSK239512 / GSK
Trial completion: Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 15, 2014
P2, N=131, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | N=1500 --> 1000 | Trial primary completion date: Nov 2016 --> Mar 2016 Active, not recruiting --> Completed
- | famotidine/ibuprofen / Generic mfg.
Enrollment closed: Open-label Safety and Pharmacokinetic Study of DUEXIS (clinicaltrials.gov) - Oct 15, 2014
P4, N=30, Active, not recruiting, Sponsor: Horizon Pharma, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | H.P. Acthar Gel (repository corticotropin injection) / Mallinckrodt
Trial completion, Phase classification: MN: Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy (clinicaltrials.gov) - Oct 15, 2014
P1, N=20, Completed, Sponsor: Mayo Clinic
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Phase classification: P1/2 --> P1
- | mycophenolate sodium / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, HEOR: The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis (clinicaltrials.gov) - Oct 11, 2014
P3, N=59, Terminated, Sponsor: Chulalongkorn University
Active, not recruiting --> Completed | Phase classification: P1/2 --> P1 N=130 --> 59 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jan 2013; Data Safety Monitoring Board concerning of the participants' safety
- Clinical: Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=17, Completed, Sponsor: Hasselt University
- Trial completion: Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=17, Completed, Sponsor: Hasselt University
N=130 --> 59 | Recruiting --> Terminated | Trial primary completion date: Dec 2011 --> Jan 2013; Data Safety Monitoring Board concerning of the participants' safety Not yet recruiting --> Completed
- glutathione PEGylated liposomal methylprednisolone (ENX-201) / BBB Therap, TTY Biopharm
Clinical: Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients (clinicaltrials.gov) - Oct 11, 2014
P1, N=54, Recruiting, Sponsor: BBB-Therapeutics B.V.
Not yet recruiting --> Completed Trial primary completion date: Sep 2014 --> Dec 2014
- Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial primary completion date: Sarilumab Effect on the Pharmacokinetics of Simvastatin (clinicaltrials.gov) - Oct 11, 2014
P1, N=14, Recruiting, Sponsor: Sanofi
Trial primary completion date: Sep 2014 --> Dec 2014 Trial primary completion date: Oct 2015 --> Mar 2016
- || ZB-168 / Zura Bio
Trial initiation date: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) (clinicaltrials.gov) - Oct 11, 2014
P1, N=60, Recruiting, Sponsor: Pfizer
Trial primary completion date: Oct 2015 --> Mar 2016 Initiation date: Jun 2014 --> Sep 2014
- HEOR: CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Cross-Sectional Study (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=60, Recruiting, Sponsor: Liverpool John Moores University
- HEOR: CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Longitudinal Study (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=25, Recruiting, Sponsor: Liverpool John Moores University
- Enrollment open, HEOR: CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Cross-Sectional Study (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=60, Recruiting, Sponsor: Liverpool John Moores University
Initiation date: Jun 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- Enrollment open, HEOR: CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Longitudinal Study (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=25, Recruiting, Sponsor: Liverpool John Moores University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||| Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
Trial primary completion date: VOLTAIRE-RA: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Oct 10, 2014
P3, N=600, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2016 --> Apr 2016
- ||| Benlysta (belimumab) / GSK
Trial initiation date: A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector (clinicaltrials.gov) - Oct 10, 2014
P2b, N=100, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Jan 2016 --> Apr 2016 Initiation date: Sep 2012 --> May 2014
- Enrollment change, Trial withdrawal, HEOR, Cost effectiveness: Treadmill Training in Chronic MS: Efficacy and Cost-effectiveness (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=0, Withdrawn, Sponsor: Department of Veterans Affairs
Initiation date: Sep 2012 --> May 2014 N=20 --> 0 | Terminated --> Withdrawn
- || Hulio (adalimumab biosimilar) / Viatris, Fujifilm Kyowa Kirin Biologics
New P3 trial: ARABESC: A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients (clinicaltrials.gov) - Oct 10, 2014
P3, N=600, Not yet recruiting, Sponsor: Fujifilm Kyowa Kirin Biologics Co.
- Enrollment open: TOYOTA: Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=14, Recruiting, Sponsor: University of Waterloo
N=20 --> 0 | Terminated --> Withdrawn Not yet recruiting --> Recruiting
- Trial completion, Trial primary completion date, Adverse events: SAR-FAME: Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=310, Completed, Sponsor: Fundación Andaluza de Reumatología
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2014
- Orencia (abatacept) / BMS
Trial completion, Combination therapy: ACCESS: Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis (clinicaltrials.gov) - Oct 10, 2014
P2, N=137, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Jun 2014 --> Oct 2014 Active, not recruiting --> Completed
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial primary completion date: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Oct 10, 2014
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Feb 2016
- || Trial primary completion date: EARLiMS: Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying Therapy (clinicaltrials.gov) - Oct 10, 2014
P4, N=434, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2015 --> Feb 2016 Trial primary completion date: Jul 2015 --> Jan 2016
- || Zinbryta (daclizumab) / Biogen, AbbVie
Trial primary completion date: SELECTION: Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) in Participants With Multiple Sclerosis Who Have Completed Study 205MS201 (NCT00390221) to Treat Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Oct 10, 2014
P2, N=520, Completed, Sponsor: Biogen Idec
Trial primary completion date: Jul 2015 --> Jan 2016 Trial primary completion date: Oct 2012 --> May 2012
- ||||| Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
Enrollment change, Combination therapy: ELEMENT 1: A Study in Adults With Type 1 Diabetes (clinicaltrials.gov) - Oct 10, 2014
P3, N=536, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Oct 2012 --> May 2012 N=400 --> 536
- | Xeljanz (tofacitinib) / Pfizer
Clinical: Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis (clinicaltrials.gov) - Oct 10, 2014
P2, N=4385, Recruiting, Sponsor: Pfizer
N=400 --> 536 Phase classification: P2/3 --> P2
- Clinical: REPLACE-BG: A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=250, Not yet recruiting, Sponsor: T1D Exchange Clinic Network Coordinating Center
- ||| Enrollment open: MyEndo-Thyroid: Thyroid Disorders in Malaysia: A Nationwide Multicentre Study (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=2500, Enrolling by invitation, Sponsor: International Islamic University Malaysia
Phase classification: P2/3 --> P2 Not yet recruiting --> Enrolling by invitation
- Victoza (liraglutide) / Novo Nordisk
Enrollment closed: Liraglutide in Type 1 Diabetes (clinicaltrials.gov) - Oct 10, 2014
P4, N=100, Active, not recruiting, Sponsor: Steno Diabetes Center
Not yet recruiting --> Enrolling by invitation Recruiting --> Active, not recruiting
- |||| Apidra (insulin glulisine) / Sanofi
Trial completion: Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 10, 2014
P4, N=64, Completed, Sponsor: Medical University of Warsaw
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||||| Plivensia (sirukumab) / J&J
Enrollment closed: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) (clinicaltrials.gov) - Oct 4, 2014
P3, N=1672, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed Recruiting --> Active, not recruiting
- | New P1/2 trial: Acceptability and Feasibility of an ACT-Based Group to Improve Diabetes Self-Management (clinicaltrials.gov) - Oct 4, 2014
P1/2, N=45, Not yet recruiting, Sponsor: Duke University
- ||| Enrollment open: Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy (clinicaltrials.gov) - Oct 4, 2014
P=N/A, N=160, Recruiting, Sponsor: University of British Columbia
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Benlysta (belimumab) / GSK
Trial primary completion date: The Evaluation of Belimumab in Myasthenia Gravis (MG) (clinicaltrials.gov) - Oct 2, 2014
P2, N=42, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Aug 2015
- | New P2 trial: The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 2, 2014
P2, N=119, Completed, Sponsor: Chengdu PLA General Hospital
- |||||| Ixifi (infliximab biosimilar) / Pfizer, Novartis
Enrollment open, Trial primary completion date, Combination therapy: A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02). (clinicaltrials.gov) - Oct 2, 2014
P3, N=614, Recruiting, Sponsor: Pfizer
Trial primary completion date: Aug 2014 --> Aug 2015 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Nov 2016
- pioglitazone / Generic mfg.
Trial completion, Trial primary completion date: Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus (clinicaltrials.gov) - Oct 2, 2014
P4, N=30, Completed, Sponsor: National Heart Institute, Mexico
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2016 --> Nov 2016 Active, not recruiting --> Completed | Trial primary completion date: Jan 2011 --> Jan 2012
- mycophenolate mofetil / Generic mfg.
Trial termination: Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (clinicaltrials.gov) - Oct 2, 2014
P3, N=184, Terminated, Sponsor: St. Joseph's Hospital and Medical Center, Phoenix
Active, not recruiting --> Completed | Trial primary completion date: Jan 2011 --> Jan 2012 Completed --> Terminated; DSMB recommended stopping the trial because of lack of effect.
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial initiation date, Trial primary completion date: CRADLE: A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers (clinicaltrials.gov) - Oct 2, 2014
P1b, N=16, Recruiting, Sponsor: UCB BIOSCIENCES, Inc.
Completed --> Terminated; DSMB recommended stopping the trial because of lack of effect. Initiation date: Jun 2014 --> Sep 2014 | Trial primary completion date: May 2015 --> Oct 2015
- ||||| Rebif (human IFN-?-1a) / EMD Serono
New P4 trial: PROCEED: Effectiveness of Rebif (clinicaltrials.gov) - Oct 2, 2014
P4, N=100, Not yet recruiting, Sponsor: Merck KGaA
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
New P1 trial, P1 data, MRI: A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients (clinicaltrials.gov) - Oct 2, 2014
P1, N=12, Not yet recruiting, Sponsor: Johns Hopkins University
- | Victoza (liraglutide) / Novo Nordisk
Enrollment closed: ADJUNCT TWO: The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes (clinicaltrials.gov) - Oct 2, 2014
P3, N=804, Active, not recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Jun 2014 --> Sep 2014 | Trial primary completion date: May 2015 --> Oct 2015 Recruiting --> Active, not recruiting
- ||| Enbrel (etanercept) / Pfizer, Amgen
Trial completion: Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=837, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Trial primary completion date: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. (clinicaltrials.gov) - Sep 30, 2014
P3, N=156, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Nov 2016 --> Feb 2016
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Trial termination, Trial primary completion date: Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=12, Terminated, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Nov 2016 --> Feb 2016 N=60 --> 12 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Jul 2014; This study was prematurely terminated due to low enrollment.
- ||| Clinical: Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=286, Active, not recruiting, Sponsor: Western University of Health Sciences